共 50 条
- [11] A randomized Phase 2a study to assess pharmacodynamics, antitumor activity and safety of intravenous BAL101553, a novel microtubule inhibitor, at two dose levels in adult patients with selected advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Kristeleit, Rebecca SophieSmith, Alan D.Haris, Noor R. MdZubairi, Ishtiaq HusainKing, Judy W.Luken, Maria Jose de MiguelD'Arcangelo, ManoloMacDonald, JulieBrown, Nicholas F.Calvert, Alan HilaryHannah, Alison L.Anderson, StephanieBachmann, FelixMaurer, MartinaSchmitt-Hoffmann, AnneLane, Heidi A.Engelhardt, Marc FrederickEvans, T. R. JeffryPlummer, RuthMolife, L. Rhoda
- [12] A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Garces, Alvaro Henrique InglesElizabeth, R.Engelhardt, FrederickGreystoke, AlastairColeman, NiamhEvans, T. R. JeffryMulholland, Paul James
- [13] Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Molife, L. RhodaImseeh, GeorgiosCapelan, MartaEl-Khouly, FatimaCresti, NicolaSmith, Alan DavidAverlon, DexterHaris, Noor Md.Stimpson, Sarah JaneGumbleton, ToddLane, Heidi A.Bachmann, FelixSchmitt-Hoffmann, AnneTzankov, AlexanderHannah, Alison L.Anderson, StephanieBette, UllrichCalvert, Alan HilaryPlummer, RuthKristeleit, Rebecca Sophie
- [14] A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Calvert, Alan HilaryGonzalez, MichaelGanguli, SushilaNg, MatthewBenafif, SarahCapelan, MartaGoldstein, RobertShah, KrunalJarvis, ClaireFlynn, MichaelForster, MartinAnderson, StephanieSchmitt-Hoffman, AnneLane, HeidiEngelhardt, MarcHannah, Alison L.Tzankov, AlexandarBachmann, FelixMolife, L. RhodaKristeleit, Rebecca
- [15] EB1-dependent long survival of glioblastoma cancer stem-like cell tumor-bearing mice after daily oral treatment with the novel Tumor Checkpoint Controller BAL101553EUROPEAN JOURNAL OF CANCER, 2018, 103 : E61 - E62Berges, R.Tchoghandjian, A.Serge, A.Figarella-Branger, D.Bachmann, F.Lane, H.Braguer, D.
- [16] A phase 1 study of oral navelbine in patients with advanced solid tumors.CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6137S - 6137SRajdev, LDai, QMani, SGoldberg, GBaker, CHoschander, SSparano, J
- [17] A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BALI 01553, a novel tumor checkpoint controller (TCC) administered as 48-hour infusion in adult patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Joerger, MarkusStathis, AnastasiosMetaxas, IoannisHess, DagmarOmlin, Aurelius GabrielSessa, Cristiana
- [18] A FIRST-IN-HUMAN STUDY OF INTRAVENOUS BAL 101553, A NOVEL MICROTUBULE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORSANNALS OF ONCOLOGY, 2015, 26Molife, L. RhodaKing, J.Smith, A.D'arcangelo, M.Brown, N.Diamantis, N.Lane, H.Hoffmann, A. H. SchmittEngelhardt, M.Plummer, R.Kristeleit, R.
- [19] Phase I safety and tolerability of once daily oral afatinib (A) in combination with gemcitabine (G) in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Zanetta, SylvieBennouna, JaafarIsambert, NicolasDe-Montserrat, HeleneSquiban, Patrick J.Delord, Jean-Pierre
- [20] The novel tubulin-binding, tumor checkpoint controller BAL101553 has differential effects on tumor vascularization with IV and oral dosing and provides superior anti-tumor activity in combination with bevacizumabCANCER RESEARCH, 2017, 77Sharma, AshishBachmann, FelixBroggini-Tenzer, AngelaGuckenberger, MatthiasLane, HeidiPruschy, Martin N.